Antibody

BioPorto Announces Interim Results for the First Nine Months of 2022

Retrieved on: 
Wednesday, November 9, 2022
Quality of life, Income, Forward-looking statement, NOTE, Risk, Nasdaq Copenhagen, CE, Disease, Mortality, Acute kidney injury, Annual report, Antibody, News, Risk assessment, Policy, Biomarker, Company, AKI, Patient, Physician, NGAL, Industry, FDA, Medical device, Pharmaceutical industry

COPENHAGEN, Denmark and BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced interim financial results for the first nine months of 2022 and business progress for the third quarter of 2022.

Key Points: 
  • The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange.
  • Given these risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements.
  • NOTE DKK/USD exchange rates used within Recent Highlights, above:
    Balance sheet measures: September 30, 2021 = 6.4220 and September 30, 2022 = 7.6287
    Income statement measures for nine months ended: September 30, 2021 = 6.1842 and September 30, 2022 = 6.9144.
  • Income statement measures for third quarter ended: September 30, 2021 = 6.2690 and September 30, 2022 = 7.3067.

Xencor to Present at Upcoming Investor Conferences

Retrieved on: 
Thursday, November 10, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Investor, Cancer, NASDAQ, Antibody, Cytokine, Degenerative disease, Patient, Technology, Company, Vaccine

Replays of the events will be available on the Xencor website for at least 30 days following the presentations.

Key Points: 
  • Replays of the events will be available on the Xencor website for at least 30 days following the presentations.
  • Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases.
  • More than 20 candidates engineered with Xencor's XmAb technology are in clinical development, and three XmAb medicines are marketed by partners.
  • Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action.

Artiva Biotherapeutics Presents Preclinical Data for AB-101, an Optimized Allogeneic NK Cell Therapy Candidate, at SITC 2022 Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Bladder cancer, IND, CD16, Annual general meeting, Immunotherapy, Cell therapy, Society for Immunotherapy of Cancer, NKG2D, NCR3, Solid, Antibody, Safety, SITC, NHL, GC, Rituximab, Breast, Cancer, Journal, Poster, Engineering, NK, Patient, ADCC, Northwest Biotherapeutics, Society, Lymphoma, FDA, Vaccine, Pharmaceutical industry, NCR1

The data were presented at the Society for Immunotherapy of Cancer (SITC) 37TH Annual Meeting in Boston.

Key Points: 
  • The data were presented at the Society for Immunotherapy of Cancer (SITC) 37TH Annual Meeting in Boston.
  • Artiva is also developing a combination therapy comprised of AB-101 and Affimed N.V.s Innate Cell Engager AFM13 for treatment of patients with relapsed/refractory CD30-positive lymphomas.
  • AB-101 is a cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers.
  • Artiva has entered into therapeutic NK cell collaborations with Merck Sharp & Dohme Corp. and with Affimed GmbH.

Recent Phase 1 DRAGON Data Show SRK-181 Continues to be Well Tolerated with Early Indications of Efficacy

Retrieved on: 
Thursday, November 10, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Neuromuscular Disorders, Blister, Safety, Immunotherapy, FAQ, Alveolar soft part sarcoma, Senior, Company, Human, Conference, Security (finance), Drug Quality and Security Act, Review, Toxic epidermal necrolysis, Securities Act of 1933, RECIST, Poster, Cancer immunotherapy, U.S. Securities and Exchange Commission, DRAGON, Cancer, Neoplasm, Itch, A2, Patient, Social media, NSCLC, Gongshi, Investor, Publication, Private Securities Litigation Reform Act, Fibrosis, Risk, Rash, Partial, UC, Antibody, Clear cell renal cell carcinoma, Clinical trial, Growth, Society, MDSC, FDA, PD, AES, Head, Rock, Squamous cell carcinoma, MEL, File, Large-cell lung carcinoma, NASDAQ, Society for Immunotherapy of Cancer, Disease, SITC, Pharmaceutical industry, Medical imaging, Vaccine, Research, Part

These early DRAGON findings of safety, target engagement and indications of efficacy support our conviction around Scholar Rocks differentiated approach and the potential role that SRK-181 may play in addressing the existing treatment hurdles.

Key Points: 
  • These early DRAGON findings of safety, target engagement and indications of efficacy support our conviction around Scholar Rocks differentiated approach and the potential role that SRK-181 may play in addressing the existing treatment hurdles.
  • We are excited to continue advancing DRAGON and look forward to sharing additional data next year.
  • The biomarker strategy for DRAGON explores early signs of SRK-181 activity, including target engagement and pathway modulation.
  • The DRAGON Phase 1 proof-of-concept clinical trial (NCT04291079) in patients with locally advanced or metastatic solid tumors is ongoing.

IgGenix Announces Presentations on Future of Food Allergy Treatment at Gordon Research Conference

Retrieved on: 
Thursday, November 10, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Immunoglobulin G, Immunoglobulin E, Research, SEQ, Incidence, Chief technology officer, Antibody, Allergy, Conference, Stanford University, Biotechnology, Therapy, Food, Vaccine

IgGenix, Inc., a pre-clinical biotechnology company taking a revolutionary approach to directly address allergic disease, today announced that three presentations will be given by IgGenix co-founders at the upcoming the Food Allergy Gordon Research Conference to be held November 13-18, 2022, in Oxnard, California.

Key Points: 
  • IgGenix, Inc., a pre-clinical biotechnology company taking a revolutionary approach to directly address allergic disease, today announced that three presentations will be given by IgGenix co-founders at the upcoming the Food Allergy Gordon Research Conference to be held November 13-18, 2022, in Oxnard, California.
  • Food allergies impact approximately 32 million Americans and 200 million people globally, and their incidence is on the rise.
  • IgGenix is a privately held biotechnology company taking a revolutionary approach to directly address food and other severe allergies by reengineering key antibodies involved in the allergic cascade.
  • Founded based on research by professors Stephen Quake, Kari Nadeau, and Derek Croote of Stanford University, IgGenix isolates allergen-specific IgE antibodies using its SEQ SIFTER discovery platform.

AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022

Retrieved on: 
Thursday, November 10, 2022
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Private Securities Litigation Reform Act, Convention center, Epitope, Translation, Risk, U.S. Securities and Exchange Commission, Conversation, Trichloroethylene, Annual general meeting, Nasdaq, Translational research, Immunotherapy, Research, Technology, Financial condition report, ABCL, Society for Immunotherapy of Cancer, TCE, Boston Convention and Exhibition Center, Antibody, CD3, Senior, Cancer, Toxicity, Disease, Drug development, Terminology, Engineering, Biotechnology, Corporation, Analysis, Result, Security (finance), VP, AACR, Society, Corporate development, SITC, Vaccine, AbCellera

The robust data package we are presenting at SITC demonstrates that our panel includes antibodies that are distinct from molecules commonly used for CD3 T-cell engager development, said Bo Barnhart, Ph.D., VP, Translational Research at AbCellera.

Key Points: 
  • The robust data package we are presenting at SITC demonstrates that our panel includes antibodies that are distinct from molecules commonly used for CD3 T-cell engager development, said Bo Barnhart, Ph.D., VP, Translational Research at AbCellera.
  • New data presented at SITC includes epitope binning analysis, revealing antibodies with species cross-reactivity that bind epitopes distinct from commonly used parental antibodies, such as SP34-2.
  • Developing bispecific antibodies that potently eliminate cancer cells without inducing toxicity has been a significant challenge limiting T-cell engager development.
  • In a proof-of-concept study, AbCellera used its OrthoMabTM bispecifics platform to create CD3 x EGFR T-cell engagers.

Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
SAN, MHC class I, PFS, Forward-looking statement, Nektar, Merck Group, Histocompatibility, U.S. Securities and Exchange Commission, Patent, Multiple myeloma, Overalls, Squamous cell carcinoma, Annual general meeting, Immunotherapy, Research, Risk, Merck, UC, Colorectal cancer, Development, Population, MHC, COVID-19, Therapy, Heparin, Failure, PD-L1, Limited partnership, Avelumab, Antibody, Safety, PD-1, Infection, Survival, SITC, Senior, Immunology, Neoplasm, Program, PEG, Clinical trial, Maintenance, Cell, B-cell lymphoma, Society for Immunotherapy of Cancer, NK, Nektar Therapeutics, Patient, Treatment, Memory, NKTR, Pfizer, Security (finance), Trial, PD, Trial of the century, Palladium, Pharmaceutical industry, Vaccine, Cancer

SAN FRANCISCO, Nov. 10, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the first presentation of preclinical data for NKTR-288 at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Key Points: 
  • NKTR-288 is a novel polyethylene glycol (PEG)-conjugate of interferon gamma (IFN-), designed to modify binding of IFN- to its substrates and optimize the duration of IFN- signaling.
  • These data support further evaluation of NKTR-288 as a monotherapy or in combination with checkpoint inhibitors in the clinical setting.
  • It highlights the potential of NKTR-288 to augment currently available PD-1 or PD-L1 treatment strategies and possibly broaden the responsive patient population."
  • Key details and takeaways from the presentation are as follows:
    Abstract 1086: "NKTR-288, a PEGylated Interferon Gamma Drug Candidate for the Treatment of Cancer", Hamel, D., et al.

Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results

Retrieved on: 
Tuesday, November 8, 2022
SAN, GLOBE, RNA transfection, Respiratory syncytial virus, Immunity, Omicron, Risk, Vaccine, Patent, Refrigeration, Severe acute respiratory syndrome coronavirus 2, Saliva, Serum, Webcast, Central Florida, Research, Injury, Tablet, RSV, HPV, Sale, Quality control, Conference call, COVID-19, Deloitte, Therapy, Immunoglobulin A, SEC, NASDAQ, Antibody, Coronavirus, BioMarin Pharmaceutical, Safety, Compliance, TLR3, Home After Three Months Away, Company, Report, Disease, Vaccination, Clinical trial, Conference, Norovirus, Immune system, Death, Certified Public Accountant, Ageing, FDA, Trial of the century, Pharmaceutical industry, Management, Merck, Vaxart

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) issued its business update today for the third quarter of 2022, during which the Company made significant progress on its oral vaccine candidates.

Key Points: 
  • ET
    SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT)issued its business update today for the third quarter of 2022, during which the Company made significant progress on its oral vaccine candidates.
  • Research and development expenses were$22.5 millionfor the third quarter of 2022, compared to$12.4 million for the third quarter of 2021.
  • General and administrative expenses were$7.0 millionfor the third quarter of 2022, compared to$5.0 million for the third quarter of 2021.
  • The Vaxart senior management team will host a conference call to discuss the business update and financial results for the third quarter of 2022 today, beginning at 4:30 p.m.

BioAtla to Participate in the Jefferies London Healthcare Conference

Retrieved on: 
Tuesday, November 8, 2022
SAN, GLOBE, Method, Conjugation, Conditional, Patent, Nasdaq, CAB, Antibody, Senior, Toxicity, Conference, AXL, Therapy, Pharmaceutical industry, Vaccine

BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services.

Key Points: 
  • BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services.
  • Utilizing its proprietary Conditionally Active Biologics (CAB) technology, BioAtla develops novel, reversibly active monoclonal antibody and other protein therapeutic product candidates.
  • CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies.
  • BioAtla has extensive and worldwide patent coverage for its CAB technology and products with more than 600 patents, more than 350 of which are issued.

Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results

Retrieved on: 
Tuesday, November 8, 2022
Investor, Traffic barrier, Pfizer, Tropism, Partnership, Research, AAIC, Family, G&A, Therapy, Exercise, Brain, Gene expression, Senior, Company, Human, Conference, SOD1, Neurocrine Biosciences, Director, Transgene, Capsid, Telephone, Cell, Board, RNA, Neurocrine, Board of directors, Gene, U.S. Securities and Exchange Commission, AAV, Private Securities Litigation Reform Act, Patient, COVID-19, Amyotrophic lateral sclerosis, Nasdaq, Corporate Affairs, Mouse, Cardiac muscle, Antibody, Toxicity, Central nervous system, CNS, Congress, Income, GLOBE, ESGCT, European Society of Gene and Cell Therapy, Conference call, Annual report, Biomarker, D, ALS, Neurology, Pharmaceutical industry, Vaccine, Fine chemical, Lithium, IND, Novartis, Voyager

CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported third quarter 2022 financial and operating results.

Key Points: 
  • ET today -
    CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported third quarter 2022 financial and operating results.
  • Voyager previously received a$30 millionupfront option grant payment and, following the close of Q3 2022, received a$10 millionoption exercise payment.
  • Collaboration Revenues: Voyager had collaboration revenue of $41.1 million for the third quarter of 2022, compared to $1.5 million for the same period in 2021.
  • ET to discuss the third quarter 2022 financial and operating results.